Innovation will be the key driver for pharma industry going forward.
Innovation will be the key driver for the pharma industry going forward and make India the pharmacy of the world, says Pankaj Patel, chairman, Cadila Healthcare. He was speaking at the India Pharmaceutical Forum, organised by the Indian Pharmaceutical Alliance (IP Alliance) in Mumbai recently.
“Where we are today is because of our capability to make the best generics. The pharma industry should work towards bridging unmet medical needs,” Patel added.
The CEO Panel on Patient Centricity and Integrated Quality Management by the CEOs of Lupin, Dr. Reddy’s Laboratories, Sun Pharmaceuticals, Cadila Healthcare, and Cipla reflected thoughts on the Indian pharmaceutical industry’s current standing and the path ahead.
Nilesh Gupta, managing director, Lupin Ltd. said, “There have been quite many changes in the pharmaceutical market globally and in India. There are a host of opportunities, which come with their own unique challenges. All the members of the IP Alliance came together to discuss and exchange information to build best practices. This reinforces the Indian Pharma Industry’s commitment to quality management.”
"There is significant room to improve quality. Patients at the core is also a major focus for IP Alliance. While the US is still the largest market of generic drugs in the world, India too has risen to the challenges. India is also a big market for generics,"added Gupta.
Satish Reddy, president, IP Alliance and chairman, Dr. Reddy’s Laboratories Ltd said, “There has been increasing pressure from the US for exporters. However, it is still the largest market for us. There has also been an increasing focus on China to tap into the emerging market of generics. With India being a major player in the generics market, we need to set the global benchmark in quality. We need to create an industry culture where people do the right thing and speak up if anything wrong happens.”
Samina Hamied, executive vice chairperson, Cipla Ltd. said, “It is important to educate and train people about quality culture across the value chain. There needs to be increased focus on quality and robustness of design. The Indian Pharma Industry has to be on a journey of continued improvement of quality systems. For this, we need to overcome the existing cultural inertia. We are focusing on respiratory, oncology and speciality business going ahead."
Source: http://www.pharmabiz.com/NewsDetails.aspx?aid=121523&sid=1
“Where we are today is because of our capability to make the best generics. The pharma industry should work towards bridging unmet medical needs,” Patel added.
The CEO Panel on Patient Centricity and Integrated Quality Management by the CEOs of Lupin, Dr. Reddy’s Laboratories, Sun Pharmaceuticals, Cadila Healthcare, and Cipla reflected thoughts on the Indian pharmaceutical industry’s current standing and the path ahead.
Nilesh Gupta, managing director, Lupin Ltd. said, “There have been quite many changes in the pharmaceutical market globally and in India. There are a host of opportunities, which come with their own unique challenges. All the members of the IP Alliance came together to discuss and exchange information to build best practices. This reinforces the Indian Pharma Industry’s commitment to quality management.”
"There is significant room to improve quality. Patients at the core is also a major focus for IP Alliance. While the US is still the largest market of generic drugs in the world, India too has risen to the challenges. India is also a big market for generics,"added Gupta.
Satish Reddy, president, IP Alliance and chairman, Dr. Reddy’s Laboratories Ltd said, “There has been increasing pressure from the US for exporters. However, it is still the largest market for us. There has also been an increasing focus on China to tap into the emerging market of generics. With India being a major player in the generics market, we need to set the global benchmark in quality. We need to create an industry culture where people do the right thing and speak up if anything wrong happens.”
Samina Hamied, executive vice chairperson, Cipla Ltd. said, “It is important to educate and train people about quality culture across the value chain. There needs to be increased focus on quality and robustness of design. The Indian Pharma Industry has to be on a journey of continued improvement of quality systems. For this, we need to overcome the existing cultural inertia. We are focusing on respiratory, oncology and speciality business going ahead."
Source: http://www.pharmabiz.com/NewsDetails.aspx?aid=121523&sid=1
Comments
Post a Comment